Literature DB >> 25925922

Tropheryma whipplei , Immunosuppression and Whipple's Disease: From a Low-Pathogenic, Environmental Infectious Organism to a Rare, Multifaceted Inflammatory Complex.

Thomas Marth1.   

Abstract

BACKGROUND: The actinobacterium Tropheryma whipplei was detected 20 years ago by molecular techniques, and following its culture has been characterized as the cause of a systemic infection known as Whipple's disease (WD). T. whipplei occurs in the environment, is prevalent only in humans, is believed to be transmitted via oral routes and to be host dependent. KEY MESSAGES: The classical form of T. whipplei infection, i.e. classical WD (CWD), is rare. It is well defined as slowly progressing chronic infection with arthralgia, diarrhea and weight loss, mostly in middle-aged men. However, current research revealed a much broader spectrum of clinical features associated with T. whipplei infection. Thus, T. whipplei may cause acute and transient infections (observed primarily in children) and the bacterium, which is found in soil and water, occurs in asymptomatic carriers as well as in CWD patients in clinical remission. In addition, T. whipplei affects isolated and localized body compartments such as heart valves or the central nervous system. Subtle immune defects and HLA associations have been described. New findings indicate that the progression of asymptomatic T. whipplei infection to clinical WD may be associated with medical immunosuppression and with immunomodulatory conditions. This explains that there is a discrepancy between the widespread occurrence of T. whipplei and the rareness of WD, and that T. whipplei infection triggered by immunosuppression presents with protean clinical manifestations.
CONCLUSIONS: This review highlights recent findings and the clinical spectrum of infection with T. whipplei and WD, focusing specifically on the role of host immunity and immunosuppression. Current concepts of the pathogenesis, diagnosis and therapy are discussed.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25925922     DOI: 10.1159/000369538

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

1.  Whipple's disease? A case report and discussion.

Authors:  Svetlana Turcan; Liudmila Tofan-Scutaru; Viorel Istrate; Vitalie Tirbu
Journal:  Med Pharm Rep       Date:  2021-08-10

Review 2.  A Massive Number of Extracellular Tropheryma whipplei in Infective Endocarditis: A Case Report and Literature Review.

Authors:  Nadji Hannachi; Florent Arregle; Hubert Lepidi; Jean-Pierre Baudoin; Frédérique Gouriet; Hélène Martel; Sandrine Hubert; Benoit Desnues; Alberto Riberi; Jean-Paul Casalta; Gilbert Habib; Laurence Camoin-Jau
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

3.  Design of a Multi-Epitope Vaccine against Tropheryma whipplei Using Immunoinformatics and Molecular Dynamics Simulation Techniques.

Authors:  Thamer H Albekairi; Abdulrahman Alshammari; Metab Alharbi; Amal F Alshammary; Muhammad Tahir Ul Qamar; Tasneem Anwar; Saba Ismail; Bilal Shaker; Sajjad Ahmad
Journal:  Vaccines (Basel)       Date:  2022-04-28

Review 4.  Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes.

Authors:  Caoimhe Egan; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2017-11-03       Impact factor: 3.464

5.  Molecular detection of Tropheryma whipplei, Cryptosporidium spp., and Giardia lamblia among celiac disease samples.

Authors:  Mostafa Sayyadi; Saeid Hosseinzadeh; Masoud Hosseinzadeh; Zahra Pourmontaseri
Journal:  J Res Med Sci       Date:  2020-12-30       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.